All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison (in HF clinic unless stated otherwise) Population Outcomes Comments Stratified by LVEF status UPSTEP trial: Karlstrom (Karlstrom , Karlstrom ) NP monitoring: Therapy increased towards guideline- target doses to reach BNP Clinical monitoring: Therapy intensified at clinician s discretion according to clinical assessment Age > 18 years, LVEF < 40%, NYHA class II-IV, worsening HF (requiring hospitalisation and/or IV support) Elevated BNP those aged < 75 years and > 300 ng/L for those aged > 75 years) despite standard treatment with ACEi/ARB and BB HTA IPD: All-cause admission by age Study papers: Quality of life Recruited ACEi/ARB: Angiotensin converting enzyme inhibitor and/or Aldosterone receptor blocker, BB: Beta-blocker, IV: Intravenous therapy, NP: natriuretic peptides including BNP and NT-proBNP Monitoring Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 